Extent of lung involvement over severity of cardiac disease for the prediction of adverse outcome in COVID-19 patients with cardiovascular disease.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 01 2021
Historique:
received: 23 06 2020
revised: 14 09 2020
accepted: 05 10 2020
pubmed: 11 10 2020
medline: 30 12 2020
entrez: 10 10 2020
Statut: ppublish

Résumé

Aim of the present study was to assess if the presence of high cardiovascular risk, left ventricle systolic dysfunction or elevated BNP or Troponin are able to independently predict the outcome of patients with known cardiac disease and COVID-19 pneumonia. From March 7th to April 28th, forty consecutive patients with known cardiac disease (chronic coronary artery disease, n=38; atrial fibrillation, n = 7; valvular disease, n = 13) referred to our emergency department for symptoms of suspected COVID-19, laboratory diagnosis of COVID-19 and typical signs of viral pneumonia at chest CT were enrolled in the study. The only predictor of the composite end-point (all cause of death + invasive ventilation + thromboembolic event) was the lung involvement % at chest CT (OR: 1.06; 95%CI: 1.01-1.11, P = 0.02). In the multivariate analysis, the lung involvement % at chest CT was the only independent predictor of the composite end-point (OR: 1.06; 95%CI: 1.01-1.11, P = 0.034). The extent of lung involvement by COVID-19 is the only independent predictor of adverse outcome of patients and is predominant over the severity of cardiac disease.

Sections du résumé

BACKGROUND
Aim of the present study was to assess if the presence of high cardiovascular risk, left ventricle systolic dysfunction or elevated BNP or Troponin are able to independently predict the outcome of patients with known cardiac disease and COVID-19 pneumonia.
METHODS AND RESULTS
From March 7th to April 28th, forty consecutive patients with known cardiac disease (chronic coronary artery disease, n=38; atrial fibrillation, n = 7; valvular disease, n = 13) referred to our emergency department for symptoms of suspected COVID-19, laboratory diagnosis of COVID-19 and typical signs of viral pneumonia at chest CT were enrolled in the study. The only predictor of the composite end-point (all cause of death + invasive ventilation + thromboembolic event) was the lung involvement % at chest CT (OR: 1.06; 95%CI: 1.01-1.11, P = 0.02). In the multivariate analysis, the lung involvement % at chest CT was the only independent predictor of the composite end-point (OR: 1.06; 95%CI: 1.01-1.11, P = 0.034).
CONCLUSIONS
The extent of lung involvement by COVID-19 is the only independent predictor of adverse outcome of patients and is predominant over the severity of cardiac disease.

Identifiants

pubmed: 33038410
pii: S0167-5273(20)33915-2
doi: 10.1016/j.ijcard.2020.10.006
pmc: PMC7543753
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

292-294

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Références

N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Eur Heart J Cardiovasc Imaging. 2020 Sep 1;21(9):1055-1056
pubmed: 32671381
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Int J Cardiol. 2020 Jul 1;310:167-168
pubmed: 32276773
Circulation. 2020 May 19;141(20):1597-1599
pubmed: 32207994

Auteurs

Daniele Andreini (D)

Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy. Electronic address: daniele.andreini@ccfm.it.

Edoardo Conte (E)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Saima Mushtaq (S)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Carlo Gigante (C)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Maria Elisabetta Mancini (ME)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Andrea Annoni (A)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Giulio Stefanini (G)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Humanitas Clinical and Research Hospital IRCCS, Rozzano, Milan, Italy.

Cecilia Agalbato (C)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Nicola Cosentino (N)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Gianluca Pontone (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Emilio Assanelli (E)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Mauro Pepi (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH